Prediabetes Stratification by Multi-omics Profile After Food Intake
Reason given: Study design changed and we are submitting a new entry under a different study.
Key facts
- Where
- Stanford, United StatesSee the site
Where in United States
- Stanford UniversityStanford, United StatesNo longer taking part
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT06005051
- Record updated
- 15 May 2025
- Original description
1 in 3 adults have prediabetes in the United States, and many of them will eventually develop diabetes, which has significant public health and economic costs. However, type 2 diabetes (T2D) and prediabetes are heterogeneous groups with different pathological mechanisms, dysfunctions in different processes, and varied disease trajectories. Patient stratifications into subtypes and personalized nutrition interventions are highly needed but not yet available. Metabolic responses (e.g., glucose excursion) after food intake provide a direct observation of personal metabolic control and its association with T2D.Read full original descriptionShow less
1 in 3 adults have prediabetes in the United States, and many of them will eventually develop diabetes, which has significant public health and economic costs. However, type 2 diabetes (T2D) and prediabetes are heterogeneous groups with different pathological mechanisms, dysfunctions in different processes, and varied disease trajectories. Patient stratifications into subtypes and personalized nutrition interventions are highly needed but not yet available. Metabolic responses (e.g., glucose excursion) after food intake provide a direct observation of personal metabolic control and its association with T2D.
The investigators hope to learn how prediabetes and type 2 diabetes evolve, and specifically what food or exercise can do to mitigate blood sugar response.
Inclusion: Be 18 years of age or older; Not be pregnant; Live close to Stanford Campus; Be generally healthy (with no apparent symptoms at the time of enrollment); Patients with prediabetes or diet-controlled or type 2 diabetes or controlled with metformin, will also be allowed to participate; Be willing to provide written informed consent for all study procedures.-.
Exclusion: are on diabetogenic medications (with the exclusion of metformin),; use of weight loss medications or specific diets,; Major organ diseases,; have malabsorptive disorders like celiac sprue or similar; history of bariatric surgery; Any medical condition that our physician believes would interfere with study participation or evaluation of results; Mental incapacity and/or cognitive impairment on the part of the patient that would preclude the adequate understanding of, or cooperation with, the study protocol; Pregnant or lactating. If a participant will become pregnant while in the study, she will be removed from the study; report heavy alcohol use,; weight change > 2 kg in the last three weeks,.